Publication | Open Access
Largest GWAS (N=1,126,563) of Alzheimer’s Disease Implicates Microglia and Immune Cells
43
Citations
70
References
2020
Year
Unknown Venue
NeurogenomicsGeneticsImmunologyGenetic EpidemiologyLargest GwasNeurochemical BiomarkersAlzheimer ’Tau AggregationSocial SciencesNeuroinflammationHuman MicrogliaAlzheimer's DiseaseDisease Implicates MicrogliaDegenerative PathologyNeurologyAging-associated DiseaseNeuroimmunologyMolecular SignalingGenetic VariantsMolecular NeuroscienceBrain-immune InteractionImmune FunctionNeurodegenerationProtective MechanismsNeurodegenerative DiseasesDementiaBiomarkersNeuroscienceMedicine
Summary Late-onset Alzheimer’s disease is a prevalent age-related polygenic disease that accounts for 50-70% of dementia cases 1 . Late-onset Alzheimer’s disease is caused by a combination of many genetic variants with small effect sizes and environmental influences. Currently, only a fraction of the genetic variants underlying Alzheimer’s disease have been identified 2,3 . Here we show that increased sample sizes allowed for identification of seven novel genetic loci contributing to Alzheimer’s disease. We highlighted eight potentially causal genes where gene expression changes are likely to explain the association. Human microglia were found as the only cell type where the gene expression pattern was significantly associated with the Alzheimer’s disease association signal. Gene set analysis identified four independent pathways for associated variants to influence disease pathology. Our results support the importance of microglia, amyloid and tau aggregation, and immune response in Alzheimer’s disease. We anticipate that through collaboration the results from this study can be included in larger meta-analyses of Alzheimer’s disease to identify further genetic variants which contribute to Alzheimer’s pathology. Furthermore, the increased understanding of the mechanisms that mediate the effect of genetic variants on disease progression will help identify potential pathways and gene-sets as targets for drug development.
| Year | Citations | |
|---|---|---|
Page 1
Page 1